Viridian Therapeutics VRDN Stock Key Catalysts Ahead Q4 2025 Profit Surprises AURA Aura Bio posts narrower than expected Q4 2025 loss yet shares drop 343 on zero quarterly revenue Market Moves Tech outpaces consumer sectors in mild downbeat trading The key trends fueling Turn Therapeutics TTRX growth potential 237 20260511 GDL Fund GDL Stock Why Operational Efficiency 059 20260420